Tpi(6)-Leu(13)-psi(CH2NH)-Leu(14)- bombesin (6-14)

an antagonist of bombesin

Also Known As:

bombesin (6-14), Tpi(6)-Leu(13)-psi(CH2NH)-Leu(14)-; RC 3095; RC-3095; L-Histidinamide, N2-((2,3,4,9-tetrahydro-1H-pyrido(3,4-b)indol-3-yl)carbonyl)-L-glutaminyl-L-tryptophyl-L-alanyl-L-valylglycyl-N-(1-(((1-(aminocarbonyl)-3-methylbutyl)amino)methyl)-3-methylbutyl)-, (1(S),6(S-(R*,R*)))-

Networked: 66 relevant articles (9 outcomes, 13 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Schwartsmann, Gilberto: 15 articles (01/2015 - 01/2006)
2.	Roesler, Rafael: 14 articles (06/2013 - 01/2006)
3.	Dal-Pizzol, Felipe: 8 articles (06/2013 - 01/2006)
4.	Petronilho, Fabricia: 5 articles (06/2013 - 08/2009)
5.	Schally, Andrew V: 4 articles (10/2012 - 03/2002)
6.	Streck, Emilio L: 4 articles (03/2011 - 08/2009)
7.	Schally, A V: 4 articles (01/2004 - 03/2000)
8.	Ritter, Cristiane: 3 articles (10/2012 - 01/2006)
9.	Schwartsmann, G: 3 articles (10/2011 - 09/2006)
10.	Rezin, Gislaine T: 3 articles (03/2011 - 08/2009)

Related Diseases

1.	Sepsis (Septicemia) 01/01/2006 - "The administration of RC-3095 (0.3 mg/kg) 6 h after sepsis induction improved survival in the CLP model, and diminished lung damage after intratracheal instillation of LPS. " 10/24/2012 - "Human patients with a clinical diagnosis of sepsis received a continuous infusion with RC-3095 (3 mg/kg, intravenous) over a period of 12 h, and plasma was collected before and after RC-3095 administration and, in a different set of patients with systemic inflammatory response syndrome (SIRS) or sepsis, GRP plasma levels were determined. " 01/10/2012 - "RC-3095 is a selective GRPR antagonist, recently found to have antiinflammatory properties in arthritis and sepsis models. " 01/01/2006 - "We determined the effects of RC-3095 in the CLP model of sepsis and in acute lung injury induced by intratracheal instillation of LPS. " 06/01/2013 - "RC-3095, a selective GRPR antagonist, was found to have antiinflammatory properties in models of arthritis, gastritis, uveitis and sepsis. "
2.	Neoplasms (Cancer) 09/01/2006 - "Considering the novelty of its mechanism of action and impressive preclinical anti-tumor activity, further studies exploiting new formulations of RC-3095 for human use, such as slow-release preparations, and analogues with a more favorable pharmacokinetics are warranted." 06/01/2009 - "In in vivo experiments, the control group displayed the largest tumors (52 +/- 15.5 mm(3)), whereas RC-3095 reduced the tumor size, with the most significant effect at the dose of 0.3 mg/kg (21 +/- 9.7 mm(3)). " 08/18/2007 - "RC-3095, a BBS/GRP antagonist, attenuated BBS-stimulated tumor growth and angiogenesis in vivo. " 10/09/1995 - "Treatment with RC-3095 induced smaller, and not significant, decreases in tumor volume and weight. " 02/15/1994 - "In mice treated with RC-3095, the tumor growth delay time was 5.8 days. "
3.	Pancreatic Neoplasms (Pancreatic Cancer) 05/08/1993 - "The number of animals with pancreatic cancers was significantly lower in the group treated with 60 micrograms/day of RC-3095 and the weight of tumorous pancreata was reduced. " 05/08/1993 - "RC-3095 exerted a dose-dependent inhibitory effect on growth of pancreatic cancers. " 02/15/1994 - "In this study, we investigated the effect of bombesin/GRP antagonist RC-3095 on the growth of CFPAC-1 human pancreatic cancer cells transplanted to nude mice or cultured in vitro. " 01/01/2014 - "The antiproliferation effects of RC-3095, gemcitabine, or the combination on pancreatic cancer were monitored in vitro. " 02/15/1994 - "Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro."
4.	Prostatic Neoplasms (Prostate Cancer) 10/15/2010 - "These findings shed light on the mechanisms of action of these analogs and support the view that the use of AN-215 and RC-3095 for blocking BN/GRP receptors for targeted therapy may be of benefit for treatment of advanced prostate cancer." 01/01/1992 - "The finding that bombesin antagonist RC-3095 inhibits the growth of PC-82 prostate cancer suggests the merit of further studies to evaluate the possible usefulness of antagonists of bombesin in the management of prostatic carcinoma." 12/16/1992 - "We have recently shown that antagonists of bombesin and gastrin-releasing peptide, including RC-3095, inhibit the growth of pancreatic, colonic, and prostatic cancers in experimental animals. " 12/01/1993 - "Combination therapy of LH-RH analogs with bombesin antagonists such as RC-3095 might be considered for improvement of hormonal therapy of prostate cancer." 12/02/1993 - "Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice."
5.	Inflammation (Inflammations) 01/01/2015 - "RC-3095, a selective GRPR antagonist, has been shown to have anti-inflammatory properties in different models of inflammation. " 10/01/2011 - "Synovial inflammation, synovial hyperplasia, pannus formation, and extensive erosive changes were all dramatically reduced in the arthritic mice treated with RC-3095. " 08/01/2010 - "RC-3095 was the only treatment to significantly reduce macroscopic and microscopic scores of inflammation as compared with the animals from the non-treated colitis group. " 09/01/2010 - "We report the effects of the gastrin-releasing peptide (GRP) receptor antagonist RC-3095 in an acute inflammation model induced by carrageenan. "

Related Drugs and Biologics

1.	Bombesin Receptors (Bombesin Receptor)
2.	Bombesin
3.	vapreotide
4.	Somatostatin (Somatotropin Release-Inhibiting Factor)
5.	Acetylcysteine (Siran)
6.	Gemcitabine
7.	Androgens
8.	Enzymes
9.	Taurine
10.	Histamine (Histamine Dihydrochloride)

Related Therapies and Procedures

1.	Ligation
2.	Subcutaneous Injections
3.	Therapeutics
4.	Aftercare (After-Treatment)
5.	Punctures